All News

Belumosudil is the first therapy within England and Wales available for the treatment of patients 12 years and older who have previously undergone a minimum of 2 lines of systemic treatment.

During or after cancer treatment, patients may experience sexual dysfunction leading to a decrease in their quality of life.

After originally releasing the Medicare Prescription Drug Inflation Rebate Program in February 2023, CMS has issued changes which address ongoing drug shortages.

Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.

Minimal residual disease testing appears to be a valuable tool for predicting outcomes and potential relapse in patients with lymphoid malignancies.

While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer.

Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.

Data from a meta-analysis may provide safety insights for future randomized clinical trials evaluating immune checkpoint blockade in the definitive setting for patients with cancer.

Data from part 2 of the phase 3 RUBY trial support the use of dostarlimab as a backbone for immunotherapy-based combinations in patients with primary advanced or recurrent endometrial cancer.

Measures should be taken to encourage more community oncologists to adopt minimal residual disease testing in patients with lymphoid malignancies, according to Georges Azzi, MD, of Holy Cross Health.

Investigators will assess the safety and preliminary clinical activity of MRBC-101 in patients with EphA5-expressing malignant solid tumors as part of a phase 1/1b trial.

The FDA did not raise any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab for squamous cell carcinoma.

The safety profile of the phase 3 RELATIVITY-123 trial is not the cause of the discontinuation, as safety is consistent with prior trials assessing the combination.

Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.

In a recent Hot Topics column, Mehmet Sitki Copur, MD, FACP, et al discussed the pros and cons of patients receiving test results early through electronic medical records.

The efficacy of HIPEC plus cytoreductive surgery appears to be consistent across ovarian cancer subgroups based on age, histological type, and pre-surgery laparoscopy in the phase 3 OVHIPEC-1 trial.

Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.

In Europe, pembrolizumab is now available as a treatment in combination with fluoropyrimidine-/platinum-containing chemotherapy for HER2-negative gastric or GEJ adenocarcinoma, as well as in combination with gemcitabine/cisplatin for locally advanced biliary tract carcinoma.

mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma.

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.

Early screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.

A regimen consisting of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide appears safe for a population of patients diagnosed with mantle cell lymphoma, as investigators report no significant dose-limiting toxicities or tumor lysis syndrome.

The current drug supply shortage is due to manufacturing issues and economic factors, both of which can be addressed, according to Jason Westin, MD, MS, FACP.

Data from a real-world study may help clinicians in treatment decision-making for those with extensive-stage small cell lung cancer who are unable to afford PD-L1 inhibitors.

Adding camrelizumab to chemotherapy appears tolerable for patients with resectable stage IIIA or IIIB non–small cell lung cancer in the phase 2 TD-FOREKNOW trial.

Treatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.

Patients with locally advanced or metastatic urothelial cancer may now receive enfortumab vedotin plus pembrolizumab following its approval by the FDA.

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

The phase 2 LuminICE study shows potential for the AFM13/AB-101 combination in treating patients with relapsed or refractory CD30-positive lymphoma.